Literature DB >> 12716040

Myeloma and race: a review of the literature.

Michael Benjamin1, Sreekanth Reddy, Otis W Brawley.   

Abstract

Multiple myeloma is an uncommon disease, with approximately 12,000 cases per year diagnosed in America. Blacks have had at least double the risk of being diagnosed with myeloma, and have had twice the mortality rate from the disease compared to whites. Research of the origins of this difference has yielded both insight and controversy. Obesity is likely a risk factor for myeloma, in both blacks and whites. Obesity is more prevalent in the black population, and this may help explain some of the increased incidence of myeloma. Also, genetic factors such as HLA antigens and family history seem to be important in explaining the differential risk of myeloma. Exposure to immunological challenges, especially urinary tract infections in black men, seems important in explaining some of the excess risk in blacks. Factors such as socioeconomic status, dietary preferences, vitamin intake, alcohol and tobacco use, either lack a consensus finding, or may not play a role in explaining the increased myeloma morbidity and mortality in blacks.

Entities:  

Mesh:

Year:  2003        PMID: 12716040     DOI: 10.1023/a:1022268103136

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  20 in total

1.  Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients.

Authors:  Hakan Kaya; Benjamin Peressini; Irfan Jawed; Danko Martincic; Ameer L Elaimy; Wayne T Lamoreaux; Robert K Fairbanks; Kevin A Weeks; Christopher M Lee
Journal:  Int J Hematol       Date:  2011-12-09       Impact factor: 2.490

Review 2.  Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites.

Authors:  A J Greenberg; C M Vachon; S V Rajkumar
Journal:  Leukemia       Date:  2011-12-23       Impact factor: 11.528

3.  True, true unrelated? Coexistence of Waldenström macroglobulinemia and cardiac transthyretin amyloidosis.

Authors:  Avinainder Singh; Hallie I Geller; Kevin M Alexander; Robert F Padera; Richard N Mitchell; Sharmila Dorbala; Jorge J Castillo; Rodney H Falk
Journal:  Haematologica       Date:  2018-04-19       Impact factor: 9.941

Review 4.  Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.

Authors:  Stephen M Ansell; Robert A Kyle; Craig B Reeder; Rafael Fonseca; Joseph R Mikhael; William G Morice; P Leif Bergsagel; Francis K Buadi; Joseph P Colgan; David Dingli; Angela Dispenzieri; Philip R Greipp; Thomas M Habermann; Suzanne R Hayman; David J Inwards; Patrick B Johnston; Shaji K Kumar; Martha Q Lacy; John A Lust; Svetomir N Markovic; Ivana N M Micallef; Grzegorz S Nowakowski; Luis F Porrata; Vivek Roy; Stephen J Russell; Kristen E Detweiler Short; A Keith Stewart; Carrie A Thompson; Thomas E Witzig; Steven R Zeldenrust; Robert J Dalton; S Vincent Rajkumar; Morie A Gertz
Journal:  Mayo Clin Proc       Date:  2010-08-11       Impact factor: 7.616

5.  Parental longevity and survival among patients with multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.

Authors:  Ingigerður S Sverrisdóttir; Sigrún H Lund; Ingemar Turesson; Magnus Björkholm; Lynn R Goldin; Ola Landgren; Sigurður Y Kristinsson
Journal:  Br J Haematol       Date:  2019-03-24       Impact factor: 6.998

6.  Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma.

Authors:  Parameswaran N Hari; Navneet S Majhail; Mei-Jie Zhang; Anna Hassebroek; Fareeha Siddiqui; Karen Ballen; Asad Bashey; Jenny Bird; Cesar O Freytes; John Gibson; Gregaory Hale; Leona Holmberg; Ram Kamble; Robert A Kyle; Hillard M Lazarus; Charles F LeMaistre; Fausto Loberiza; Angelo Maiolino; Philip L McCarthy; Gustavo Milone; Nancy Omondi; Donna E Reece; Matthew Seftel; Michael Trigg; David Vesole; Brendan Weiss; Peter Wiernik; Stephanie J Lee; J Douglas Rizzo; Paulette Mehta
Journal:  Biol Blood Marrow Transplant       Date:  2009-11-14       Impact factor: 5.742

Review 7.  Update on therapeutic options in Waldenström macroglobulinemia.

Authors:  Xavier Leleu; Julie Gay; Aldo M Roccaro; Anne-Sophie Moreau; Stephanie Poulain; Remy Dulery; Berenice Bro Des Champs; Daniela Robu; Irene M Ghobrial
Journal:  Eur J Haematol       Date:  2009-01       Impact factor: 2.997

8.  African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States.

Authors:  Talha Badar; Parameswaran Hari; Omar Dávila; Raphael Fraser; Baldeep Wirk; Binod Dhakal; Cesar O Freytes; Cesar Rodriguez Valdes; Cindy Lee; David H Vesole; Ehsan Malek; Gerhard C Hildebrandt; Heather Landau; Hemant S Murthy; Hillard M Lazarus; Jesus G Berdeja; Kenneth R Meehan; Melhem Solh; Miguel Angel Diaz; Mohamed A Kharfan-Dabaja; Natalie S Callander; Nosha Farhadfar; Qaiser Bashir; Rammurti T Kamble; Ravi Vij; Reinhold Munker; Robert A Kyle; Saurabh Chhabra; Shahrukh Hashmi; Siddhartha Ganguly; Sundar Jagannath; Taiga Nishihori; Yago Nieto; Shaji Kumar; Nina Shah; Anita D'Souza
Journal:  Cancer       Date:  2020-09-23       Impact factor: 6.860

9.  Body mass index, physical activity, and risk of multiple myeloma.

Authors:  Brenda M Birmann; Edward Giovannucci; Bernard Rosner; Kenneth C Anderson; Graham A Colditz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-07       Impact factor: 4.254

10.  Waldenstrom macroglobulinemia.

Authors:  Xavier Leleu; Aldo M Roccaro; Anne-Sophie Moreau; Sophie Dupire; Daniela Robu; Julie Gay; Evdoxia Hatjiharissi; Nicholas Burwik; Irene M Ghobrial
Journal:  Cancer Lett       Date:  2008-06-13       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.